RICERCA ITALIANA     

FIRB simili:

• 1 - FARMACOGENETICA E FARMACOGENOMICA DELLE EPILESSIE REFRATTARIE
• 2 - Identificazione ed analisi funzionale delle alterazioni molecolari e geniche che caratterizzano i tumori della mammella ormono-responsivi
• 3 - Modulazione razionale dell'attività antitumorale di farmaci "classici" tramite intervento selettivo su specifiche cascate regolatorie
• 4 - BILANCIO OSPITE-TUMORE NELLA TERAPIA MEDICA DELLE NEOPLASIE: RUOLO DI NF-kB
• 5 - Sviluppo di molecole innovative in grado di curare malattie neurodegenerative e neuroinfiammatorie.
• 6 - Globuli rossi come "drug carriers"
• 7 - Modelli di dipendenza: correlati molecolari e funzionali.
• 8 - Caratterizzazione genetico-molecolare delle neoplasie umane: le leucemie mieloidi acute ed i sarcomi.
• 9 - PROFILO GENOMICO DEI DISORDINI LINFOPROLIFERATIVI ACUTI E CRONICI DELL'UOMO PER LO SVILUPPO DI NUOVE PROPOSTE CLASSIFICATIVE, MARCATORI DI PROGNOSI E STRATEGIE TERAPEUTICHE INNOVATIVE.
• 10 - Plasticità sinaptica e riparazione del danno cerebrale

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA

Classificazione brevettuale

• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Lombardia

Bibliografia

· Altamura AC, Boin F, Maes M. HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 10, 1-4, 1999.
· Angelucci F., Mathe A.A., Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J. Neurosci Res 2000 Jun 15; 60 (6):783-94.
· Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346, 281-2, 1995.
· Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, Kerwin RW. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 8, 481-4,1998.
· Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW. Pharmacogenetic prediction of clozapine response. Lancet 355, 1615-6, 2000 a.
· Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW. Difficulties in replication of results. Lancet 356, 1359-60, 2000 b.
· Bailey DS, Bondar A, Furness LM. Pharmacogenomics - it's not just pharmacogenetics. Curr Opin Biotechnol. 9, 595-601, 1998.
· Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport. 11, 2017-20, 2000.
· Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, KriegJC, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry. 3, 76-80, 1998.
· Carlsson A, Hansson LO, Waters N, Carlsson ML. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry Suppl. 37, 2-6, 1999.
· Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes. 45, 1455-62, 1996.
· Cichon S, Nothen MM, Rietschel M, Propping P. Pharmacogenetics of schizophrenia. Am J Med Genet. 97, 98-106, 2000.
· Connolly G.P. Fibroblast models of neurological disorders: fluorescence measurement studies. TiPS May 1998 (Vol.19)
· Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol. 19, 325-54, 1999.
· Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry. 4, 418-28, 1999.
· Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm. 10, 109-15, 2001.
· Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-91, 1999.
· Gram LF. Le basi psicofarmacocinetiche della psicofarmacoresistenza, 17-24. In: Psicofarmacoresistenza. Problemi e prospettive. Altamura AC, Gnocchi G, Monteleone P, Muscettola G eds. Idelson, Napoli, 1990.
· Hirsch SR, Das I, Garey LJ, de-Belleroche J. A pivotal role for glutamate in the pathogenesis of schizophrenia and its cognitive function. Pharmacol Biochem Behav 56, 797-802, 1997
· Humphries C, Mortimer A, Hirsch S, de-Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 7, 2051-2055, 1996.
· Ilani T., Ben-Shachar D., Strous R.D., Mazor M., Sheinkman A., Kotler M. and Fuchs S. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. PNAS January 16, 2001 (Vol.98).
· Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250, 186-200, 2001.
· Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci. 15, 711-6, 1997.
· Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225, 1999.
· Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 156, 312-4, 1999.
· Kushima Y, Hama T, Hatanaka H. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium from fetal and postnatal rat midbrains. Neurosci Res 13, 267-80, 1992.
· Lieberman RP, Van Putten T, Marshall BD et al. Optimal drug and behavior theraphy for treatment refractory schizophrenic patients Am J Psychiatry 151, 756-759, 1994.
· Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura G, Pioli R, Boin F et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10, 119-124, 2000.
· Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania:effects of neuroleptics and mood stabilizers. J Psychiatr Res 29, 141-152, 1995
· Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry. 47, 252-66, 2000.
· Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor-alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71, 11-17, 1997.
· Mousa A, SeigerA, Kjaeldgaard A, Bakhiet M. Human first trimester forebrain cells express genes for inflammatory and anti-inflammatory cytokines. Cytokine. 11, 55-60, 1999.
· Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophrenia Res 26, 227-233, 1997.
· Nawa H, Takahashi M, Patterson PH. Cytokine and growth factor involvement in schizophrenia-support for the developmental model. Mol Psychiatry 5, 594-603, 2000.
· Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 51, 912-7, 1994.
· Rietschel M, Kennedy JL, Macciardi F, Meltzer HY. Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. Schizophr Res 37, 191-6, 1999.
· Scharfetter J, Chaudhry HR, Hornik K, Fuchs K, Sieghart W, Kasper S, Aschauer HN. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol. 10, 17-20, 1999.
· Slager SL, Schaid DJ. Case-control studies of genetic merkers:power and sample size approximations for armitage's test for trend. Hum Hered 52, 149-53, 2001.
· Torgerson JS, Carlsson B, Stenlof K, Carlsson LM, Bringman E, Sjostrom L. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J Clin Endocrinol Metab. 84, 4197-203, 1999.
· Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 24, 59-73, 2001.

Parole Chiave

farmacogenetica; antipsicotici; marcatori periferici; modelli animali di patologie psichiatriche; polimorfismi genici; farmacoresistenza